GBT Global Blood Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

GBT [NASD]

Global Blood Therapeutics, Inc.

Healthcare | Biotechnology | USA

financial highlights | statements

Index	-	P/E	-	EPS (ttm)	-3.03	Insider Own	4.70%	Shs Outstand	55.81M	Perf Week	4.99%
Market Cap	2.35B	Forward P/E	-	EPS next Y	-4.03	Insider Trans	-2.27%	Shs Float	49.54M	Perf Month	-10.91%
Income	-135.20M	PEG	-	EPS next Q	-0.87	Inst Own	98.30%	Short Float	9.62%	Perf Quarter	-12.67%
Sales	-	P/S	-	EPS this Y	-11.30%	Inst Trans	12.37%	Short Ratio	6.29	Perf Half Y	12.28%
Book/sh	11.26	P/B	3.73	EPS next Y	-10.40%	ROA	-35.70%	Target Price	72.46	Perf Year	43.76%
Cash/sh	9.74	P/C	4.32	EPS next 5Y	37.00%	ROE	-38.70%	52W Range	24.02 - 68.05	Perf YTD	6.86%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-38.21%	Beta	-
Dividend %	-	Quick Ratio	23.10	Sales past 5Y	-	Gross Margin	-	52W Low	75.03%	ATR	2.62
Employees	147	Current Ratio	23.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	39.67	Volatility	5.42% 5.68%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-45.90%	Profit Margin	-	Rel Volume	1.02	Prev Close	41.35
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 07	Payout	-	Avg Volume	757.47K	Price	42.05
Recom	1.80	SMA20	-8.96%	SMA50	-8.69%	SMA200	-5.69%	Volume	772,214	Change	1.69%

May-08-18

Reiterated

SunTrust

Buy

$80 → $77

Mar-21-18

Downgrade

Morgan Stanley

Overweight → Equal-Weight

Feb-28-18

Reiterated

Cantor Fitzgerald

Overweight

$61 → $72

Feb-14-18

Initiated

Janney

Buy

Jan-23-18

Initiated

William Blair

Outperform

Dec-14-17

Reiterated

Needham

Buy

$51 → $70

Dec-01-17

Initiated

H.C. Wainwright

Buy

$73

Sep-21-17

Initiated

Needham

Buy

$51

Aug-08-17

Reiterated

JP Morgan

Overweight

$44 → $46

Apr-18-17

Initiated

SunTrust

Buy

$56

Mar-21-17

Resumed

Wedbush

Outperform

$73

Mar-16-17

Initiated

Cantor Fitzgerald

Overweight

$61

Mar-02-17

Initiated

Instinet

Buy

$50

Jan-04-17

Initiated

JP Morgan

Overweight

Nov-01-16

Initiated

ROTH Capital

Buy

$47

Oct-25-16

Reiterated

Wedbush

Outperform

$66 → $73

Sep-30-16

Initiated

Wells Fargo

Outperform

Mar-02-16

Reiterated

Wedbush

Outperform

$94 → $66

Sep-08-15

Initiated

Wedbush

Outperform

Sep-08-15

Initiated

Morgan Stanley

Overweight

$67

Jun-21-18 11:04AM	3 Killer Stocks Trading at Unfair Discounts TheStreet.com
Jun-15-18 01:06PM	Here's Why Shares of Global Blood Therapeutics Inc Are Falling Today Motley Fool -14.88%
11:33AM	Global Blood Therapeutics Shares Plunge After Sickle Cell Candidate Shows Reduced Effect Benzinga
02:30AM	GBT Announces New Phase 2a Voxelotor Data in Adolescents with Sickle Cell Disease (SCD) at 23rd European Hematology Association (EHA) Congress GlobeNewswire
Jun-14-18 07:05AM	Free Technical Reports on Gilead Sciences and Three Additional Biotech Equities ACCESSWIRE
Jun-13-18 02:55PM	Hematology Conference Could Spur Some of Biotech's Outperformers Bloomberg
Jun-08-18 08:30AM	GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease (SCD) Program at Foundation for Sickle Cell Disease Researchs 12th Annual Symposium GlobeNewswire
Jun-05-18 04:05PM	GBT Announces New Employment Inducement Grants GlobeNewswire
Jun-04-18 07:35AM	Consolidated Research: 2018 Summary Expectations for ManTech International, Rapid7, Global Blood Therapeutics, CONSOL Coal Resources LP, Ryanair, and Yandex N.V. Fundamental Analysis, Key Performance Indications GlobeNewswire
May-25-18 08:40AM	Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options Zacks
May-23-18 03:00AM	Stocks To Watch: Global Blood Therapeutic Sees RS Rating Jump To 83 Investor's Business Daily
May-19-18 10:00AM	Even Momentum Traders Should Study Stock Charts TheStreet.com
May-18-18 07:31PM	Global Blood Therapeutics Incs (NASDAQ:GBT) Profit Outlook Simply Wall St.
May-17-18 10:30AM	GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease Program at 23rd European Hematology Association (EHA) Congress GlobeNewswire
May-11-18 12:25PM	Having Some Good Luck With Biotech Names TheStreet.com +5.66%
May-09-18 01:52PM	Markets Make an Art of Unpredictability TheStreet.com
May-08-18 12:03PM	Markets Confused by Trump's Upcoming Iran Decision TheStreet.com +7.96%
May-07-18 04:58PM	Global Blood: 1Q Earnings Snapshot Associated Press
04:05PM	GBT Reports Recent Business Progress and First Quarter 2018 Financial Results GlobeNewswire
May-04-18 08:30AM	GBT Announces New Employment Inducement Grants GlobeNewswire
Apr-27-18 07:30AM	[$$] Biotechs Make Headway in Battle Against Sickle Cell Disease The Wall Street Journal
Apr-10-18 07:35AM	Factors of Influence in 2018, Key Indicators and Opportunity within Global Blood Therapeutics, Wix, Changyou, BT Group, Golar LNG, and NantHealth New Research Emphasizes Economic Growth GlobeNewswire +7.65%
Apr-03-18 04:05PM	GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
04:05PM	GBT Announces New Employment Inducement Grants GlobeNewswire
Mar-22-18 08:30AM	Todays Research Reports on Trending Tickers: Global Blood Therapeutics and Sangamo Therapeutics ACCESSWIRE
Mar-21-18 11:59AM	Turning Neutral: Morgan Stanley Downgrades Sarepta, Loxo Oncology, Global Blood Therapeutics Benzinga -5.00%
08:43AM	Why Global Blood Therapeutics (GBT) Could Be Positioned for a Slump Zacks
Mar-15-18 04:05PM	GBT Announces New Employment Inducement Grants GlobeNewswire
07:31AM	Better Know Biotech: 3 Highfliers That Ought to Be on Your Radar Motley Fool
Mar-14-18 08:10AM	Research Report Identifies Supernus Pharmaceuticals, Celestica, Global Blood Therapeutics, BioTime, CyberArk Software, and Tivity Health, Inc. with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-12-18 02:00PM	5 Stocks That Are Showing Signs of Reversing TheStreet.com -5.42%
08:00AM	Global Blood Therapeutics Announces Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Mar-08-18 10:00PM	Global Blood Therapeutics Announces Pricing of Public Offering of 4,000,000 Shares of Common Stock GlobeNewswire -5.40%
07:23PM	Is Global Blood Therapeutics Incs (NASDAQ:GBT) Liquidity As Good As Its Solvency? Simply Wall St.
04:01PM	Global Blood Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Mar-06-18 08:00AM	GBT Appoints Industry Leader David L. Johnson as Chief Commercial Officer GlobeNewswire
Mar-05-18 04:05PM	GBT Announces Participation at Upcoming Investor Conferences in March GlobeNewswire
04:05PM	GBT Announces New Employment Inducement Grants GlobeNewswire
Feb-28-18 05:04AM	Global Blood reports 4Q loss Associated Press
Feb-27-18 04:07PM	GBT Reports Recent Business Progress and Fourth Quarter and Year-End 2017 Financial Results GlobeNewswire
08:07AM	This could be the next $1 billion drug, if patients get on board MarketWatch
Feb-15-18 10:47AM	With an Eye on Biotech, Here's Today's Trading Thesis TheStreet.com
Feb-07-18 04:05PM	GBT Announces Participation at the Leerink Partners 7th Annual Global Healthcare Conference GlobeNewswire +6.04%
10:53AM	The Confidence in the Dip Buyers Has Weakened TheStreet.com
Feb-05-18 12:39PM	Here's Why Global Blood Therapeutics Inc. Soared 47.1% in January Motley Fool -5.06%
Jan-29-18 08:01AM	Novo Nordisk remains on hunt for biopharma deals Reuters
Jan-23-18 12:22PM	William Blair Values Global Blood Therapeutics' Stock At $80 Benzinga +6.12%
Jan-13-18 10:32AM	3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jan-10-18 10:31AM	Selling Action Is Upon Us TheStreet.com +17.60%
Jan-09-18 01:13PM	Healthcare Stocks Breakout: Pain Therapeutics, Inc. (PTIE), Global Blood Therapeutics Inc (GBT) SmarterAnalyst +19.07%
12:35PM	Why Global Blood Therapeutics Inc Is Rising Today Motley Fool
08:00AM	GBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of Sickle Cell Disease (SCD) GlobeNewswire
Jan-03-18 04:05PM	GBT to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-22-17 09:00AM	GBT Appoints Wendy L. Yarno to Board of Directors GlobeNewswire
Dec-15-17 09:03AM	Global Blood Therapeutics Prices a $100.0 Million Common Stock Public Offering GlobeNewswire -7.99%
Dec-14-17 04:01PM	Global Blood Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Dec-12-17 04:59PM	Why This Biotech Stock Is Defying A Hematology-Related Pitfall Investor's Business Daily -14.24%
03:42PM	This Is Why Global Blood Therapeutics Inc. Is Sinking Today Motley Fool
11:24AM	Is Global Blood Therapeutics Incs (undefined:GBT) CEO Overpaid Relative To Its Peers? Simply Wall St.
Dec-11-17 02:25PM	Life-Shortening Blood Disease Gets Rush of Research Bloomberg
10:12AM	Morgan Stanley: Global Blood Therapeutics 'Clearly Encouraged' By Sickle Cell Therapy Data Benzinga
07:00AM	GBT Announces Presentation of Six Studies at ASH Supporting Voxelotor Sickle Cell Disease (SCD) Program GlobeNewswire
Dec-09-17 10:00AM	GBT Announces New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell Disease (SCD) GlobeNewswire
Nov-30-17 04:05PM	Global Blood Therapeutics Announces New Employment Inducement Grants GlobeNewswire +5.48%
03:42PM	Global Blood Therapeutics, Inc. Fundamental Analysis : November 30, 2017 Capital Cube
Nov-13-17 08:00AM	Global Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSMB) for Phase 3 HOPE Study in Sickle Cell Disease GlobeNewswire
Nov-07-17 04:05PM	Global Blood Therapeutics Announces Participation at the Stifel 2017 Healthcare Conference GlobeNewswire -6.35%
Nov-03-17 12:43PM	Markets Get Back to Business as Usual TheStreet.com +6.27%
Nov-02-17 07:00PM	Global Blood reports 3Q loss Associated Press
04:05PM	Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results GlobeNewswire
Nov-01-17 09:00AM	Global Blood Therapeutics Announces Upcoming Data Presentations Supporting Sickle Cell Disease Program at 59th American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Oct-30-17 05:10PM	Global Blood Therapeutics Inc. Jumped as Much as 14% on This News Motley Fool +12.52%
Oct-28-17 02:15PM	Global Blood Therapeutics Announces Presentation of Case Study Demonstrating Positive Effect of Voxelotor (GBT440) in a Sickle Cell Disease Patient with Severe and Symptomatic Anemia GlobeNewswire
Oct-24-17 08:00AM	Global Blood Therapeutics Announces Approval of First-in-Class Voxelotor as Nonproprietary Name for GBT440 GlobeNewswire
06:51AM	Global Blood Therapeutics stock declines after forsaking half its drug pipeline MarketWatch
Oct-23-17 09:15AM	DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers TheStreet.com
07:24AM	Global Blood Therapeutics stock drops 11.5% after discontinuation of pulmonary fibrosis therapy MarketWatch
Oct-11-17 08:00AM	Global Blood Therapeutics Announces Presentation of New Data Showing Positive Effect of GBT440 on Sickle Cell Disease Patient with Variant Genotype GlobeNewswire
Oct-05-17 03:00AM	Global Blood Therapeutic Earns Relative Strength Rating Upgrade Investor's Business Daily
Oct-04-17 01:08PM	Steven Cohen Doubles Down on Sickle Cell Disease Therapeutics Company Global Blood GuruFocus.com +8.92%
Oct-03-17 08:00AM	Global Blood Therapeutics Announces Upcoming Presentations of GBT440 Data at Two Sickle Cell Disease Meetings in October GlobeNewswire
Sep-26-17 04:05PM	Global Blood Therapeutics Announces New Employment Inducement Grants GlobeNewswire
Sep-21-17 10:21AM	One Thing To Consider Before Buying Global Blood Therapeutics Inc (GBT) Simply Wall St. -5.07%
Sep-14-17 03:00AM	Global Blood Therapeutic Sees IBD RS Rating Climb To 71 Investor's Business Daily
Sep-06-17 08:00AM	Global Blood Therapeutics To Convene Sickle Cell Disease Influencers at Annual Sickle Cell Disease (SCD) Therapeutics Conference GlobeNewswire
Sep-05-17 08:00AM	Global Blood Therapeutics Receives Rare Pediatric Disease Designation from FDA for GBT440 for Treatment of Sickle Cell Disease (SCD) GlobeNewswire -6.27%
Aug-30-17 04:05PM	Global Blood Therapeutics Announces Upcoming Participation in Multiple Investor Conferences in September GlobeNewswire
Aug-09-17 04:05PM	Global Blood Therapeutics Announces Participation at the 2017 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-07-17 11:57PM	Global Blood reports 2Q loss Associated Press
04:05PM	Global Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2017 Financial Results GlobeNewswire
Jul-26-17 04:05PM	Global Blood Therapeutics Announces New Employment Inducement Grants GlobeNewswire
Jul-10-17 08:00AM	Global Blood Therapeutics Expands Ongoing Phase 2a HOPE-KIDS 1 Study into Younger Pediatric Population GlobeNewswire
Jul-03-17 08:31AM	Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options Zacks +5.30%
Jun-28-17 09:29AM	Global Blood Shares Pop on Priority Designation; Kite Pharma Rises on Patent News: Biotech Movers TheStreet.com +9.09%
08:31AM	Global Blood Therapeutics stock surges 5% on eligibility for European priority drug program MarketWatch
08:00AM	Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD) GlobeNewswire
Jun-23-17 02:30AM	Global Blood Therapeutics Announces New Data Supporting Ongoing Clinical Development of GBT440 in Adolescents with Sickle Cell Disease GlobeNewswire
Jun-06-17 04:05PM	Global Blood Therapeutics Announces Participation at the Goldman Sachs 38th Annual Global Healthcare Conference GlobeNewswire
May-18-17 04:00PM	Global Blood Therapeutics Announces Upcoming Presentation of GBT440 Data in Adolescents with Sickle Cell Disease at European Hematology Associations 22nd Congress GlobeNewswire
May-01-17 04:10PM	Global Blood reports 1Q loss Associated Press +6.22%

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its lead product candidate is voxelotor, an oral once-daily therapy that modulates hemoglobin's affinity for oxygen, which is in Phase III clinical trials in adult and adolescent patients with sickle cell disease (SCD). The company is also involved in evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trials of adolescent and pediatric patients with SCD; and other research and development activities that are in pre-clinical phase. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Choi Jung	See Remarks	May 17	Option Exercise	3.40	1,400	4,760	137,477	May 21 04:36 PM
Choi Jung	See Remarks	May 17	Sale	48.25	3,000	144,750	136,077	May 21 04:36 PM
Choi Jung	See Remarks	Apr 17	Option Exercise	3.40	1,400	4,760	139,077	Apr 19 04:05 PM
Choi Jung	See Remarks	Apr 17	Sale	45.50	3,000	136,500	137,677	Apr 19 04:05 PM
Choi Jung	See Remarks	Mar 16	Option Exercise	3.40	1,400	4,760	140,677	Mar 20 05:30 PM
Choi Jung	See Remarks	Mar 16	Sale	54.15	3,000	162,450	139,277	Mar 20 05:30 PM
Sham Hing	See Remarks	Mar 07	Option Exercise	0.49	10,714	5,250	98,215	Mar 09 05:30 PM
Calhoun Lesley Ann	See Remarks	Mar 05	Sale	60.35	99	5,975	388	Mar 05 05:00 PM
Choi Jung	See Remarks	Feb 16	Option Exercise	3.40	1,400	4,760	142,277	Feb 21 06:10 PM
Choi Jung	See Remarks	Feb 16	Sale	62.95	3,000	188,850	140,877	Feb 21 06:10 PM
Radovich Peter	See Remarks	Feb 01	Sale	57.30	812	46,528	6,817	Feb 02 08:17 PM
Radovich Peter	See Remarks	Jan 23	Option Exercise	1.61	30,000	48,300	33,581	Jan 25 08:09 PM
Radovich Peter	See Remarks	Jan 23	Sale	60.00	30,000	1,800,000	3,581	Jan 25 08:09 PM
Choi Jung	See Remarks	Jan 17	Option Exercise	3.40	1,400	4,760	137,778	Jan 18 07:59 PM
Choi Jung	See Remarks	Jan 17	Sale	52.85	3,000	158,550	134,778	Jan 18 07:59 PM
Radovich Peter	See Remarks	Jan 10	Option Exercise	1.61	15,000	24,150	17,684	Jan 11 09:48 PM
Radovich Peter	See Remarks	Jan 10	Sale	50.00	15,000	750,000	2,684	Jan 11 09:48 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 19	Buy	38.00	175,000	6,650,000	4,889,066	Dec 19 08:22 PM
Choi Jung	See Remarks	Dec 18	Option Exercise	3.40	1,400	4,760	136,655	Dec 20 05:12 PM
Choi Jung	See Remarks	Dec 18	Sale	36.55	3,000	109,650	135,255	Dec 20 05:12 PM
Choi Jung	See Remarks	Nov 17	Option Exercise	3.40	1,400	4,760	138,255	Nov 21 04:30 PM
Choi Jung	See Remarks	Nov 17	Sale	39.75	3,000	119,250	136,855	Nov 21 04:30 PM
Radovich Peter	Senior VP, Operations	Oct 30	Sale	35.00	12,500	437,500	0	Oct 31 08:15 PM
HOMCY CHARLES J	Director	Oct 27	Sale	34.09	15,600	531,770	67,728	Oct 27 05:15 PM
HOMCY CHARLES J	Director	Oct 26	Sale	33.93	54,400	1,845,781	83,328	Oct 27 05:15 PM
Choi Jung	See Remarks	Oct 17	Option Exercise	3.40	1,400	4,760	139,855	Oct 18 06:19 PM
Choi Jung	See Remarks	Oct 17	Sale	32.65	3,000	97,950	138,455	Oct 18 06:19 PM
Choi Jung	See Remarks	Sep 29	Option Exercise	3.40	1,400	4,760	141,455	Oct 02 05:27 PM
Choi Jung	See Remarks	Sep 29	Sale	30.00	3,000	90,000	140,055	Oct 02 05:27 PM
Choi Jung	See Remarks	Aug 31	Option Exercise	3.40	1,400	4,760	143,055	Sep 05 06:36 PM
Radovich Peter	See Remarks	Aug 31	Sale	30.00	2,410	72,300	2,684	Sep 05 06:37 PM
Choi Jung	See Remarks	Aug 31	Sale	30.00	3,000	90,000	141,655	Sep 05 06:36 PM
Sham Hing	See Remarks	Aug 02	Option Exercise	0.49	21,428	10,500	81,504	Aug 03 04:36 PM
PATRICK DEVAL L	Director	Jul 25	Option Exercise	11.97	27,053	323,730	27,053	Jul 27 05:49 PM
PATRICK DEVAL L	Director	Jul 25	Sale	29.69	27,053	803,204	0	Jul 27 05:49 PM
Choi Jung	See Remarks	Jul 21	Option Exercise	3.40	1,400	4,760	144,655	Jul 25 07:02 PM
Choi Jung	See Remarks	Jul 21	Sale	30.00	3,000	90,000	143,255	Jul 25 07:02 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience